Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist. (Q37926954)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Natale D'Alessandro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Daniela Di Lisi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular Toxicology

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

93-107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Congestive heart failure during imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Vascular and renal effects of anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Thromboembolic events with lenalidomide-based therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Sudden death during doxorubicin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cisplatin-induced atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Drug-induced atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Nitrosomethylurea-Induced Lymphomas in Thymectomized Mice, in Relation to Thymus-Dependent and Independent Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Role of dobutamine echocardiography in detection of myocardial viability for predicting outcome after revascularization in ischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Repetitive Dobutamine Stress Echocardiography for the Prediction of Anthracycline Cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Analysis of regional left ventricular function by cineventriculography, cardiac magnetic resonance imaging, and unenhanced and contrast-enhanced echocardiography: a multicenter comparison of methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Plasma endothelin‐1 As a marker for doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Endothelins: a possible mechanism of cytostatics-induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Novel insights into the role of cardiotrophin-1 in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cancer chemotherapy induces cardiotoxicity by targeting cardiac stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

The promise of human induced pluripotent stem cells for research and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Altered Na+ channels promote pause-induced spontaneous diastolic activity in long QT syndrome type 3 myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Drug- and non-drug-associated QT interval prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12012-011-9141-Z

10.1007/S12012-011-9141-Z

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21894547%20AND%20SRC:MED&resulttype=core&format=json